Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Exp Cell Res ; 397(2): 112358, 2020 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-33160998

RESUMO

The fundamental question about the functionality of in vitro derived human primordial germ cell-like cells remains unanswered, despite ongoing research in this area. Attempts have been made to imitate the differentiation of human primordial germ cells (hPGCs) and meiocytes in vitro from human pluripotent stem cells (hPSCs). A defined system for developing human haploid cells in vitro is the challenge that scientists face to advance the knowledge of human germ cell development. To develop human primordial germ cell-like cells (hPGCLCs) from human pluripotent stem cells (hPSCs) that are capable of giving rise to haploid cells, we applied a sequential induction protocol via the early mesodermal push of female human embryonic and induced pluripotent stem cells. BMP4-induced early mesoderm-like cells showed significant alterations in their expression profiles toward early (PRDM1 and NANOS3) and late (VASA and DAZL) germ cell markers. Furthermore, using retinoic acid (RA), we induced hPGCLCs in embryoid bodies and identified positive staining for the meiotic initiation marker STRA8. Efforts to find the cells exhibiting progression to meiosis were unsuccessful. The validation by the expression of SCP3 did not correspond to the natural pattern. Regarding the 20-day meiotic induction, the derived hPGCLCs containing two X-chromosomes were unable to complete the meiotic division. We observed the expression of the oocyte marker PIWIL1 and PIWIL4. RNAseq analysis and cluster dendrogram showed a similar clustering of hPGCLC groups and meiotic like cell groups as compared to previously published data. This reproducible in vitro model for deriving hPGCLCs provides opportunities for studying the molecular mechanisms involved in the specification of hPGCs. Moreover, our results will support a further elucidation of gametogenesis and meiosis of female hPGCs.


Assuntos
Diferenciação Celular , Corpos Embrioides/citologia , Regulação da Expressão Gênica no Desenvolvimento , Células Germinativas/citologia , Células-Tronco Pluripotentes Induzidas/citologia , Meiose , Células Cultivadas , Corpos Embrioides/metabolismo , Feminino , Perfilação da Expressão Gênica , Células Germinativas/metabolismo , Humanos , Técnicas In Vitro , Células-Tronco Pluripotentes Induzidas/metabolismo , RNA-Seq
2.
Histol Histopathol ; 33(11): 1189-1199, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29845594

RESUMO

Despite recent advances in bioengineered therapies, wound healing remains a serious clinical problem. In acute full-thickness wounds, it is desirable to replace both the damaged dermis and epidermis in a single procedure. This approach requires appropriate properties of tissue-engineered dressings to support simultaneous regenerative processes in the dermis and epidermis while they are temporally separated in the natural wound healing process. In this study, a collagen-based scaffold inhabited by skin cells was employed. Its ability to stimulate the skin repair of full-thickness excisional splinting wounds in a murine model was evaluated in comparison with that of acellular collagen and commercially available gelatin porous sponge Spongostan®. The study showed that cell-based skin equivalent promoted the immediate filling of the wound bed and provided simultaneous reorganization of the dermal component into highly vascularized granulation-like tissue and rapid epithelialization, thus improving the quality of healing. Inflammation was delayed and less pronounced. In contrast, acellular collagen and especially Spongostan® failed to demonstrate similar results. The porous structure of Spongostan® prevented effective long-term epithelialization and impeded the formation of an adequate connective tissue at the wound bed.


Assuntos
Curativos Biológicos , Colágeno/uso terapêutico , Alicerces Teciduais , Cicatrização , Animais , Células Cultivadas , Camundongos
3.
Stem Cell Res Ther ; 6: 15, 2015 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-25888992

RESUMO

INTRODUCTION: In recent years, mesenchymal stem cells (MSCs) have been demonstrated to play an important role in carcinogenesis. However, the effect of MSCs on tumor and metastasis development and the mechanisms underlying the interaction of cancer and stem cells are not completely understood. This study investigated the effect of MSCs on breast cancer metastasis formation by using the methods of in vivo fluorescence and luminescence imaging. METHODS: MSCs were isolated from bone marrow of normal donors, characterized, and genetically labeled with luciferase (luc2). The effects of MSCs on MDA-MB-231 cancer cell proliferation were evaluated in conditioned medium from MSCs. To generate lung metastases, MDA-MB-231 cells stably expressing red fluorescent protein Turbo FP650 were injected intravenously into nude mice. On day 10 after the cancer cell injection, mice were injected via the tail vein with MSCs-luc2 cells (the MET+MSCs group). Animals that received the injection of MDA-MB-231-Turbo FP650 alone (the MET group) and no injections (the intact control group) served as controls. Fluorescence and bioluminescence imaging was performed for monitoring of the metastasis formation and MSC distribution in the recipient's body. RESULTS: We found that the proliferative activity of the cancer cells in the presence of MSC conditioned medium was lower than that of the cells grown in conventional culture medium. The metastasis formation in the MET+MSCs group was delayed in time as compared with the MET group. Macroscopic and histological examination of isolated lungs 8 weeks after cancer cell injection showed that the total number of metastases in animals of the MET+MSCs group was significantly lower. Using bioluminescence imaging in vivo, we found that MSCs-luc2 cells survived in the host animal for at least 7 weeks and re-migrated to the lung 6 to 7 weeks after injection. Immunohistochemical analysis revealed the presence of MSCs-luc2 in metastases and lung tissue. CONCLUSIONS: Long-term in vivo bioluminescence imaging of intravenously injected MSCs-luc2 cells showed distribution of MSCs to the lungs and abdominal organs within the first 2 to 3 weeks and re-migration to the lungs in weeks 6 to 7. It was found that MSCs reduced the proliferative activity of cancer cells in vitro and lung metastasis formation in mice.


Assuntos
Transformação Celular Neoplásica/patologia , Meios de Cultivo Condicionados/farmacologia , Neoplasias Pulmonares/secundário , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais/metabolismo , Animais , Neoplasias da Mama/patologia , Proliferação de Células , Modelos Animais de Doenças , Feminino , Neoplasias Pulmonares/patologia , Camundongos , Camundongos Nus , Transplante de Neoplasias , Imagem Óptica/métodos
4.
Eur J Pharmacol ; 471(2): 141-7, 2003 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-12818702

RESUMO

Functions of thrombin as a modulator of inflammation and tissue repair are mediated by the proteinase-activated receptor (PAR) family. Some of these effects may be induced by activation of mast cells. To characterize the degranulation of rat peritoneal mast cells in response to PAR agonists, the effects of thrombin, trypsin and peptide agonists of PARs (PAR-AP, proteinase-activated receptor-activating peptides) on secretion were investigated. The release of beta-hexosaminidase by thrombin (0.01-1 microM) was concentration-dependent and mediated via PAR(1), as evidenced by cathepsin G (100 microM)-induced inactivation of PAR(1) and thrombin-stimulated PAR(1) desensitization. Trypsin (1 microM) accelerated histamine secretion. The PAR(1)-AP, TRAP (SFFLRN, 1-100 microM) and the PAR(2)-AP SLIGRL (5-100 microM) caused the release of histamine, and beta-hexosaminidase from inflammatory mast cells were obtained from a model of acute peritonitis in rats. Relative to the response to compound 48/80, the thrombin- and TRAP-induced release of beta-hexosaminidase was higher in inflammatory mast cells than in the control. This suggests that additional exposure of PAR(1) on mast cells to PAR agonists or an increase in PARs sensitivity to PAR agonists probably occurred during acute inflammation.


Assuntos
Inflamação/fisiopatologia , Mastócitos/metabolismo , Mastócitos/fisiologia , Receptores Ativados por Proteinase/agonistas , Doença Aguda , Animais , Degranulação Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Histamina/química , Injeções Intraperitoneais , Cetotifeno/administração & dosagem , Cetotifeno/farmacocinética , Masculino , Mastócitos/efeitos dos fármacos , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/farmacocinética , Peritônio/citologia , Peritônio/efeitos dos fármacos , Peritônio/metabolismo , Peritonite/induzido quimicamente , Ratos , Ratos Wistar , Receptor PAR-1/efeitos dos fármacos , Receptores Ativados por Proteinase/efeitos dos fármacos , Receptores de Trombina/efeitos dos fármacos , Tioglicolatos/administração & dosagem , Tioglicolatos/efeitos adversos , Trombina/administração & dosagem , Trombina/farmacocinética , Tripsina/administração & dosagem , Tripsina/farmacocinética , beta-N-Acetil-Hexosaminidases/química , p-Metoxi-N-metilfenetilamina/administração & dosagem , p-Metoxi-N-metilfenetilamina/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA